Business Description
Pfizer Inc
NAICS : 325412
SIC : 2834
Share Class Description:
XKAZ:PFE_KZ: Ordinary SharesCompare
Compare
Traded in other countries / regions
PFE.USAPFE.Canada0Q1N.UKPFE.GermanyPFE.ArgentinaPFE.MexicoPFIZ34.Brazil1PFE.ItalyPFE.AustriaPFE_KZ.KazakhstanPFE.SwitzerlandPFE.PeruPFE.BulgariaPFE.ChilePFECO.ColombiaPFE.Ukraine IPO Date
2019-03-14Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 |
N/A
|
N/A
| |||
Equity-to-Asset | 0.43 |
N/A
|
N/A
| |||
Debt-to-Equity | 0.71 |
N/A
|
N/A
| |||
Debt-to-EBITDA | 3.71 |
N/A
|
N/A
| |||
Interest Coverage | 6.42 |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.03 | |||||
Beneish M-Score | -2.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -14.7 | |||||
3-Year EBITDA Growth Rate | -25.7 |
N/A
|
N/A
| |||
3-Year EPS without NRI Growth Rate | -21.2 |
N/A
|
N/A
| |||
3-Year FCF Growth Rate | -29.5 |
N/A
|
N/A
| |||
3-Year Book Growth Rate | -3.7 |
N/A
|
N/A
| |||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -8.34 |
N/A
|
N/A
| |||
Future 3-5Y Total Revenue Growth Rate Estimate | -4.24 |
N/A
|
N/A
|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.97 |
N/A
|
N/A
| |||
9-Day RSI | 68.56 |
N/A
|
N/A
| |||
14-Day RSI | 58.23 |
N/A
|
N/A
| |||
3-1 Month Momentum % | -8.91 |
N/A
|
N/A
| |||
6-1 Month Momentum % | -1.56 |
N/A
|
N/A
| |||
12-1 Month Momentum % | 2.19 |
N/A
|
N/A
|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.25 |
N/A
|
N/A
| |||
Quick Ratio | 0.94 |
N/A
|
N/A
| |||
Cash Ratio | 0.38 |
N/A
|
N/A
| |||
Days Inventory | 240.77 |
N/A
|
N/A
| |||
Days Sales Outstanding | 72.23 |
N/A
|
N/A
| |||
Days Payable | 109.59 |
N/A
|
N/A
|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 6.83 |
N/A
|
N/A
| |||
Dividend Payout Ratio | 0.56 |
N/A
|
N/A
| |||
3-Year Dividend Growth Rate | 2.4 |
N/A
|
N/A
| |||
Forward Dividend Yield % | 6.83 |
N/A
|
N/A
| |||
5-Year Yield-on-Cost % | 7.66 |
N/A
|
N/A
| |||
3-Year Average Share Buyback Ratio | -0.4 |
N/A
|
N/A
| |||
Shareholder Yield % | 8.85 |
N/A
|
N/A
|
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.51 |
N/A
|
N/A
| |||
Operating Margin % | 27.24 |
N/A
|
N/A
| |||
Net Margin % | 11.83 |
N/A
|
N/A
| |||
EBITDA Margin % | 27.13 |
N/A
|
N/A
| |||
FCF Margin % | 14.98 |
N/A
|
N/A
| |||
OCF Margin % | 18.93 |
N/A
|
N/A
| |||
ROE % | 8.35 |
N/A
|
N/A
| |||
ROA % | 3.61 |
N/A
|
N/A
| |||
ROIC % | 8.62 |
N/A
|
N/A
| |||
3-Year ROIIC % | -121.21 |
N/A
|
N/A
| |||
ROC (Joel Greenblatt) % | 55.91 |
N/A
|
N/A
| |||
ROCE % | 6.18 |
N/A
|
N/A
| |||
Years of Profitability over Past 10-Year | 10 |
N/A
|
N/A
| |||
Moat Score | 8 |
N/A
|
N/A
| |||
Tariff Resilience Score | 6 |
N/A
|
N/A
|
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 18.89 |
N/A
|
N/A
| |||
Forward PE Ratio | 8.62 |
N/A
|
N/A
| |||
PE Ratio without NRI | 8.05 |
N/A
|
N/A
| |||
Price-to-Owner-Earnings | 28.81 |
N/A
|
N/A
| |||
PS Ratio | 2.24 |
N/A
|
N/A
| |||
PB Ratio | 1.57 |
N/A
|
N/A
| |||
Price-to-Free-Cash-Flow | 14.94 |
N/A
|
N/A
| |||
Price-to-Operating-Cash-Flow | 11.81 |
N/A
|
N/A
| |||
EV-to-EBIT | 18.13 |
N/A
|
N/A
| |||
EV-to-Forward-EBIT | 9.89 |
N/A
|
N/A
| |||
EV-to-EBITDA | 11.18 |
N/A
|
N/A
| |||
EV-to-Forward-EBITDA | 8.05 |
N/A
|
N/A
| |||
EV-to-Revenue | 3.03 |
N/A
|
N/A
| |||
EV-to-Forward-Revenue | 3.1 |
N/A
|
N/A
| |||
EV-to-FCF | 20.25 |
N/A
|
N/A
| |||
Price-to-GF-Value | 0.95 |
N/A
|
N/A
| |||
Price-to-Projected-FCF | 0.66 |
N/A
|
N/A
| |||
Price-to-Median-PS-Value | 0.59 |
N/A
|
N/A
| |||
Earnings Yield (Greenblatt) % | 5.52 |
N/A
|
N/A
| |||
FCF Yield % | 6.72 |
N/A
|
N/A
| |||
Forward Rate of Return (Yacktman) % | -3.24 |
N/A
|
N/A
|
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Pfizer Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 63,314 | ||
| EPS (TTM) ($) | 1.31 | ||
| Beta | N/A | ||
| 3-Year Sharpe Ratio | -0.96 | ||
| 3-Year Sortino Ratio | -1.13 | ||
| Volatility % | 15.32 | ||
| 14-Day RSI | 58.23 | ||
| 14-Day ATR ($) | 0.46 | ||
| 20-Day SMA ($) | 24.34 | ||
| 12-1 Month Momentum % | 2.19 | ||
| 52-Week Range ($) | 23 - 29 | ||
| Shares Outstanding (Mil) | 5,699.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pfizer Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pfizer Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 10:00 | In 107 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 106 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 10:00 | In 16 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 15 days | ||
| conference call with investment analysts | 2026-08-04 10:00 | In 15 days | ||
| USD 0.430000 Cash Dividend | 2026-07-24 | In 3 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 14:00 | 25.44 (-0.62%) | ||
| USD 0.430000 Cash Dividend | 2026-05-08 | 26.49 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 10:00 | 26.42 (-1.23%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 26.42 (-1.23%) |
Show
Entries
Pfizer Inc Frequently Asked Questions
What is Pfizer Inc(XKAZ:PFE_KZ)'s stock price today?
The current price of XKAZ:PFE_KZ is $25.17. The 52 week high of XKAZ:PFE_KZ is $29.00 and 52 week low is $23.00.
When is next earnings date of Pfizer Inc(XKAZ:PFE_KZ)?
The next earnings date of Pfizer Inc(XKAZ:PFE_KZ) is 2026-08-05 Est..
Does Pfizer Inc(XKAZ:PFE_KZ) pay dividends? If so, how much?
The Dividend Yield % of Pfizer Inc(XKAZ:PFE_KZ) is 6.83% (As of Today), Highest Dividend Payout Ratio of Pfizer Inc(XKAZ:PFE_KZ) was 0.89. The lowest was 0.24. And the median was 0.52. The Forward Dividend Yield % of Pfizer Inc(XKAZ:PFE_KZ) is 6.83%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Pfizer Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers